RECRO PHARMA INC (REPH)
Common Stock
Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation
With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers’ Goal of...
Recro Reports Fourth Quarter and Year End 2021 Financial Results
Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele ...
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern...
Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention
SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing...
Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
Latest Appointment Continues Build-Out of Leadership Team for San Diego Operations...
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing...
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.
Recro Reports Third Quarter 2021 Financial Results
Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and...
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka
Agreement Establishes Recro as Commercial Supplier for Otsuka Deal Validates Recro’s “Second Source” Strategy of Supporting Commercial Programs as...
Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic
New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturing” Contract with NIH...
Recro Reports Inducement Grants For New Staff
Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego...
Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?
Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.
Recro Signs Renewable Energy Agreement With Georgia Power
Investment in Renewable Energy Credits Represents Key Component of Company’s Ongoing Environmental Sustainability Program
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO
Recro Reports Second Quarter 2021 Financial Results
Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
Conference Call and Webcast Scheduled for Monday, August 9, 2021 at 4:30 p.m. Eastern
Recro Appoints Erica Raether as Vice President of People, Culture and ESG
Innovative Human Resources Executive with Deep Expertise Developing and Implementing People-Focused Strategies to Support Employee Engagement, Advance ESG Objectives and Achieve Operational Goals
Recro Enters Development and Manufacturing Agreement With New Client
Recro Reports Inducement Grants for New Staff
Recro Appoints Laura L. Parks, Ph.D. to Board of Directors
Experienced Biopharma Executive with Track Record of Driving Commercial and Operational Success at Global CDMOs